How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

AbelZeta Receives FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma

calendar_today November 10, 2026 person Sarah Kelly domain abelzeta-pharma

U.S. Food and Drug Administration (FDA) has granted both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to Prizloncabtagene Autoleucel (Prizlon-cel), also known as A-CAR039, an investigational anti-CD20/CD19 bispecific CAR-T therapy for the treatment of patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL). The post AbelZeta Receives FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma appeared first on AbelZeta .

open_in_new Read original post